



Sneha Ramakrishna

Instructor, Pediatrics - Hematology & Oncology

CLINICAL OFFICES

- **Pediatric Hematology/Oncology**

725 Welch Rd MC 5913

Palo Alto, CA 94304

Tel (650) 497-8953

Fax (650) 497-8959

Bio

BIO

Sneha Ramakrishna, M.D., is an Instructor of Pediatrics in the Division of Hematology and Oncology, working with Dr Crystal Mackall. Dr. Ramakrishna obtained her B. A. from the University of Chicago and her M.D. from the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. She completed her residency training in Pediatrics at the Children's Hospital of Philadelphia and her fellowship in Pediatric Hematology/Oncology at the Johns Hopkins/National Cancer Institute combined program. Her research focuses on identifying mechanisms of relapse in patients following chimeric antigen receptor (CAR) T cell therapies and optimizing both CAR design and tumor sensitivity to improve long-term success of CAR T cell therapies.

CLINICAL FOCUS

- Hematology/Oncology

ACADEMIC APPOINTMENTS

- Instructor, Pediatrics - Hematology & Oncology

HONORS AND AWARDS

- Young Investigator Award, Hyundai Hope on Wheels (2020-2022)
- ASH Abstract Achievement Award, American Society of Hematology (2017)
- Research Scholar, Howard Hughes Medical Institute (2010)

PROFESSIONAL EDUCATION

- Board Certification: Hematology/Oncology, American Board of Pediatrics (2019)
- Board Certification, American Board of Pediatrics , Hematology/Oncology (2019)
- Board Certification: Pediatrics, American Board of Pediatrics (2015)
- Fellowship: Johns Hopkins and National Cancer Institute Ped Hematology and Oncology Training (2018) MD
- Residency: Children's Hospital of Philadelphia Pediatric Residency (2015) PA
- Medical Education: Case Western Reserve School of Medicine (2012) OH

Research & Scholarship

CLINICAL TRIALS

- CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies, Recruiting
- GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG), Recruiting
- Phase I CD19/CD22 Chimeric Antigen Receptor T Cells in Peds Recurrent/Refractory B Cell Malignancies, Recruiting

Publications

PUBLICATIONS

- **Prospects and Challenges for Use of CAR T Cell Therapies in Solid Tumors.** *Expert opinion on biological therapy*
Ramakrishna, S., Barsan, V., Mackall, C.
2020
- **Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.** *Current oncology reports*
Barsan, V., Ramakrishna, S., Davis, K. L.
2020; 22 (2): 11
- **Supercharging your CAR.** *Blood*
Ramakrishna, S., Davis, K. L.
2020; 135 (9): 593–94
- **Modulation of Target Antigen Density Improves CAR T Cell Functionality and Persistence.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Ramakrishna, S., Highfill, S. L., Walsh, Z., Nguyen, S. M., Lei, H., Shern, J. F., Qin, H., Kraft, I. L., Stetler-Stevenson, M., Yuan, C. M., Hwang, J. D., Feng, Y., Zhu, et al
2019
- **Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22** *MOLECULAR THERAPY-ONCOLYTICS*
Qin, H., Ramakrishna, S., Nguyen, S., Fountaine, T. J., Ponduri, A., Stetler-Stevenson, M., Yuan, C. M., Haso, W., Shern, J. F., Shah, N. N., Fry, T. J.
2018; 11: 127–37
- **CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.** *Nature medicine*
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., Shalabi, H., Fountaine, T. J., Shern, et al
2017
- **Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas** *CANCER IMMUNOLOGY RESEARCH*
Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M. G., Orentas, R. J., Mackall, C. L.
2016; 4 (10): 869-880